Insmed Inc (INSM)vsPrime Medicine, Inc. Common Stock (PRME)
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
PRME
Prime Medicine, Inc. Common Stock
$3.52
-1.68%
HEALTHCARE · Cap: $646.38M
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 12992% more annual revenue ($606.42M vs $4.63M). PRME leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
INSM
Hold39
out of 100
Grade: F
PRME
Avoid19
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -146.8% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bull Case : PRME
PRME has a balanced fundamental profile.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Bear Case : PRME
The primary concerns for PRME are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
INSM profiles as a turnaround stock while PRME is a value play — different risk/reward profiles.
PRME carries more volatility with a beta of 2.58 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
PRME generates stronger free cash flow (-38M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 19/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Prime Medicine, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Prime Medicine, Inc. is a pioneering biotechnology firm that aims to transform healthcare with its groundbreaking Prime Editing technology, designed for accurate genetic modifications at the DNA level. The company is advancing a strong pipeline of innovative therapies targeting serious diseases, such as genetic disorders and cancer, backed by exceptional intellectual property protections. Committed to addressing critical unmet medical needs, Prime Medicine is strategically positioned to be a key player in the genetic medicine arena, showing significant potential for growth and a meaningful contribution to the evolving biopharmaceutical landscape.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?